LPS binding protein (LBP) and CD14 play key roles in promoting innate immunity to Gram-negative bacteria by transferring LPS to the signaling receptor complex, MD-2/Toll-like receptor 4 (TLR4). LBP and soluble CD14 (sCD14) can also inhibit responses to LPS by mechanisms that depend on their concentration and environment; during acute inflammation and infection, their concentrations increase in plasma and extravascular fluids. Whereas low concentrations of LBP enhance responses to LPS, high LBP concentrations can inhibit LPS bioactivity in vitro and in vivo. sCD14 also inhibits cell responses by diverting LPS from membrane-bound CD14 (mCD14) and by promoting LPS efflux from cell-surface mCD14 and transferring it to plasma lipoproteins. In vivo studies support the hypothesis that sCD14 has systemic anti-inflammatory effects, whereas in the tissues it may have pro-inflammatory effects that increase resistance to bacteria. Likewise, LBP increases resistance to Gram-negative bacteria by rapidly triggering pro-inflammatory responses to LPS. Thus, the dual stimulatory and inhibitory mechanisms of sCD14 and LBP may benefit the infected host by promoting inflammation in local sites, where it is needed, while at the same time preventing potentially detrimental systemic responses to LPS.
Hailman E., Vasselon T., Kelley M. et al. Stimulation of macrophages and neutrophils by complexes of lipopolysaccharide and soluble CD14. J Immunol1996; 156: 4384—4390.
2.
Frey EA, Miller DS, Jahr TG et al. Soluble CD14 participates in the response of cells to lipopolysaccharide . J Exp Med1992; 176: 1665—1671.
3.
Pugin J., Schürer-Maly C-C., Leturcq D., Moriarty A., Ulevitch RJ, Tobias PSLipopolysaccharide activation of human endothelial and epithelial cells is mediated by lipopolysaccharide-binding protein and soluble CD14. Proc Natl Acad Sci USA1993; 90: 2744—2748.
Haziot A., Rong G-W., Bazil V., Silver J., Goyert SMRecombinant soluble CD14 inhibits LPS-induced tumor necrosis factor-α production by cells in whole blood. J Immunol1994; 152: 5868—5876.
6.
Haziot A., Rong GW, Lin XY, Silver J., Goyert SMRecombinant soluble CD14 prevents mortality in mice treated with endotoxin (lipopolysaccharide). J Immunol1995; 154: 6529—6532.
7.
Kitchens RL, Thompson PA, Viriyakosol S., O'Keefe GE, Munford RSPlasma CD14 decreases monocyte responses to LPS by transferring cell-bound LPS to plasma lipoproteins. J Clin Invest2001; 108: 485—493.
8.
Kitchens RL, Wolfbauer G., Albers JJ, Munford RSPlasma lipoproteins promote the release of bacterial lipopolysaccharide from the monocyte cell surface. J Biol Chem1999 ; 274: 34116—34122.
9.
Hiki N., Berger D., Dentener MA et al. Changes in endotoxin-binding proteins during major elective surgery: important role for soluble CD14 in regulation of biological activity of systemic endotoxin. Clin Diagn Lab Immunol1999; 6: 844—850.
10.
Landmann R. , Zimmerli W., Sansano S. et al. Increased circulating soluble CD14 is associated with high mortality in Gram-negative septic shock. J Infect Dis1995; 171: 639—644.
11.
Landmann R., Reber AM, Sansano S., Zimmerli W.Function of soluble CD14 in serum from patients with septic shock. J Infect Dis1996; 173: 661—668.
12.
Burgmann H., Winkler S., Locker GJ et al. Increased serum concentration of soluble CD14 is a prognostic marker in Gram-positive sepsis. Clin Immunol Immunopathol1996; 80: 307—310.
13.
Stelter F., Witt S., Fürll B., Jack RS, Hartung T., Schütt C.Different efficacy of soluble CD14 treatment in high- and low-dose LPS models . Eur J Clin Invest1998; 28: 205—213.
14.
Shuto Y., Kataoka M., Higuchi Y., Matsuura K., Hijiya N., Yamamoto S.Roles of CD14 in LPS-induced liver injury and lethality in mice pretreated with Propionibacterium acnes. Immunol Lett2004; 94: 47—55.
15.
Tamura Y., Higuchi Y., Kataoka M., Akizuki S., Matsuura K., Yamamoto S.CD14 transgenic mice expressing membrane and soluble forms: comparisons of levels of cytokines and lethalities in response to lipopolysaccharide between transgenic and non-transgenic mice. Int Immunol1999; 11: 333—339.
16.
Fong Y., Marano MA, Moldawer LL et al. The acute splanchnic and peripheral tissue metabolic response to endotoxin in humans. J Clin Invest1990 ; 85: 1896—1904.
17.
Scoazec JY, Feldmann G.In situ immunophenotyping study of endothelial cells of the human hepatic sinusoid: results and functional implications. Hepatology1991; 14: 789—797.
18.
Knolle PA, Löser E., Protzer U. et al. Regulation of endotoxin-induced IL-6 production in liver sinusoidal endothelial cells and Kupffer cells by IL-10. Clin Exp Immunol1997; 107: 555—561.
19.
Knolle PA, Gerken G.Local control of the immune response in the liver. Immunol Rev2000; 174: 21—34.
20.
Cauwels A., Frei K., Sansano S. et al. The origin and function of soluble CD14 in experimental bacterial meningitis. J Immunol1999; 162: 4762—4772.
21.
Lee JW, Paape MJ, Elsasser TH, Zhao X.Recombinant soluble CD14 reduces severity of intramammary infection by Escherichia coli. Infect Immun2003; 71: 4034—4039.
22.
Schiff DE, Kline L., Soldau K. et al. Phagocytosis of Gram-negative bacteria by a unique CD14-dependent mechanism. J Leukoc Biol1997; 62: 786—794.
23.
Vesy CJ, Kitchens RL, Wolfbauer G., Albers JJ, Munford RSLPS binding protein and phospholipid transfer protein release lipopolysaccharides from Gram-negative bacterial membranes. Infect Immun1999; 68: 2410—2417.
24.
Hailman E., Lichenstein HS, Wurfel MM et al. Lipopolysaccharide (LPS)-binding protein accelerates the binding of LPS to CD14. J Exp Med1994; 179: 269—277.
25.
Gegner JA, Ulevitch RJ, Tobias PSLipopolysaccharide (LPS) signal transduction and clearance. Dual roles for LPS binding protein and membrane CD14. J Biol Chem1995; 270: 5320—5326.
26.
Dunzendorfer S., Lee HK, Soldau K., Tobias PSTLR4 is the signaling but not the lipopolysaccharide uptake receptor. J Immunol2004; 173: 1166—1170.
27.
Jack RS, Fan X., Bernhelden M. et al. Lipopolysaccharide-binding protein is required to combat a murine Gram-negative bacterial infection. Nature1997; 389: 742—744.
28.
Yang KK, Dorner BG, Merkel U. et al. Neutrophil influx in response to a peritoneal infection with Salmonella is delayed in lipopolysaccharide-binding protein or CD14-deficient mice. J Immunol2002; 169: 4475—4480.
29.
Knapp S., de Vos AF, Florquin S., Golenbock DT, van der Poll T.Lipopolysaccharide binding protein is an essential component of the innate immune response to Escherichia coli peritonitis in mice. Infect Immun2003; 71: 6747—6753.
30.
Fan MH, Klein RD, Steinstraesser L. et al. An essential role for lipopolysaccharide-binding protein in pulmonary innate immune responses. Shock2002 ; 18: 248—254.
31.
Heumann D., Lauener R., Ryffel B.The dual role of LBP and CD14 in response to Gram-negative bacteria or Gram-negative compounds. J Endotoxin Res2003; 9: 381—384.
32.
Weber JR, Freyer D., Alexander C. et al. Recognition of pneumococcal peptidoglycan: an expanded, pivotal role for LPS binding protein. Immunity2003 ; 19: 269—279.
33.
Branger J., Florquin S., Knapp S. et al. LPS-binding protein-deficient mice have an impaired defense against Gram-negative but not Gram-positive pneumonia. Int Immunol2004; 16: 1605—1611.
34.
Echtenacher B., Freudenberg MA, Jack RS, Mannel DNDifferences in innate defense mechanisms in endotoxemia and polymicrobial septic peritonitis. Infect Immun2001; 69: 7271—7276.
35.
Lamping N., Dettmer R., Schröder NW et al. LPS-binding protein protects mice from septic shock caused by LPS or Gram-negative bacteria. J Clin Invest1998; 101: 2065—2071.
36.
Zweigner J. , Gramm HJ, Singer OC, Wegscheider K., Schumann RRHigh concentrations of lipopolysaccharide-binding protein in serum of patients with severe sepsis or septic shock inhibit the lipopolysaccharide response in human monocytes. Blood2001; 98: 3800—3808.
37.
Martin TR, Mathison JC, Tobias PS et al. Lipopolysaccharide binding protein enhances the responsiveness of alveolar macrophages to bacterial lipopolysaccharide. Implications for cytokine production in normal and injured lungs. J Clin Invest1992; 90: 2209—2219.
38.
Vreugdenhil Ace, Snoek Amp, Greve JW, Buurman WALipopolysaccharide-binding protein is vectorially secreted and transported by cultured intestinal epithelial cells and is present in the intestinal mucus of mice. J Immunol2000; 165: 4561—4566.
39.
Bannerman DD , Paape MJ, Hare WR, Sohn EJIncreased levels of LPS-binding protein in bovine blood and milk following bacterial lipopolysaccharide challenge. J Dairy Sci2003; 86: 3128—3137.
40.
Wurfel MM, Kunitake ST, Lichenstein H., Kane JP, Wright SDLipopolysaccharide (LPS)-binding protein is carried on lipoproteins and acts as a cofactor in the neutralization of LPS. J Exp Med1994; 180: 1025—1035.
41.
Kitchens RL , Thompson PA, Munford RS, O'Keefe GE. Acute inflammation and infection maintain circulating phospholipid levels and enhance lipopolysaccharide binding to plasma lipoproteins. J Lipid Res2003; 44: 2339—2348.
42.
Gioannini TL , Teghanemt A., Zarember KA, Weiss JPRegulation of interactions of endotoxin with host cells. J Endotoxin Res2003; 9: 401—408.
43.
Thompson PA , Tobias PS, Viriyakosol S., Kirkland TN, Kitchens RLLipopolysaccharide (LPS)-binding protein inhibits responses to cell-bound LPS. J Biol Chem2003 ; 278: 28367—28371.
